Overview

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

Status:
Not yet recruiting

Trial end date:
2023-06-30

Target enrollment:

Participant gender:

Summary

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

He Huang

Collaborator:

Gracell Biotechnology Ltd.